Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

NCT01784068 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Nilotinib followed by treatment-free

Sponsor

Novartis Pharmaceuticals